Merck KGaA (MRK) Earnings Call Transcript & Summary

March 5, 2026

Deutsche Boerse Xetra DE Health Care Pharmaceuticals earnings 81 min

Earnings Call Speaker Segments

Operator

operator
#1

Good day, everyone, and thank you for joining the Merck Investor and Analyst Conference Call covering the fourth quarter and full year 2025. Just a quick note that everyone attending today is in listen-only mode. At this point I'll pass things over to Florian Schroeder, our Head of Investor Relations, and he will guide you through the conference. Florian, over to you.

Florian Schroeder

executive
#2

Thanks so much, Sarah. I'd like to extend a warm welcome to all of you who are with us for the Q4 and full year 25 earnings call. I'm Florian Schroeder, Head of Investor Relations at Merck. It's a real pleasure to have with me Belén Garijo, our Group CEO, Helene von Roeder, our Group CFO, and Kai Beckmann, Deputy Chairman of the Executive Board. Later, for the Q&A portion, Jean-Charles Wirth, CEO of Life Science, and Danny Bar-Zohar, CEO of Healthcare, will also be joining us. As you've certainly seen, we announced some upcoming changes to the executive board not long ago. I'm happy to say that Benjamin Hein, who becomes CEO of Electronics as of May first, will be with us later today to give a brief introduction. With that, I'm glad to turn things over to Belén to get us started.

Belén Garijo

executive
#3

Thank you, Florian, and good afternoon to all of you. I'd also like to extend a very warm welcome from my end, and I appreciate your joining us today. Kindly turn to slide 5 of the presentation, since that's where I'll begin. As all of you are aware, 2025 was marked on the whole by a difficult macro and geopolitical backdrop, and even so, we achieved solid organic growth in net sales and EBITDA pre. Our Life Science business is back to organic growth, propelled by demand from our Process Solutions customers returning to normal levels. Healthcare kept up solid organic performance in spite of certain pressures in the market, and Electronics bounced back in H2, owing to sustained AI-driven demand in Semiconductor Solutions. Most importantly, we have met our most recent guidance for both the group and our business sectors, along with market expectations for the group. That said, let's turn to the fourth-quarter highlights on slide number six. Group organic sales growth reached a solid +2.6% in Q4. We achieved profitable growth backed by all three sectors, with group EBITDA pre rising +3.1% organically. Life Science maintained good momentum, posting organic sales growth of 4%. I'm especially happy with our Process Solutions business, where sales climbed by close to 10% organically, even with comparables on the rise.

Belén Garijo

executive
#4

Order intake is still solid, and our book-to-bill remains comfortably higher than one. In Healthcare, organic sales grew +3%, driven primarily by CM&E at the franchise level. The rare disease business we recently set up contributed an impressive five percentage points of inorganic growth, which is ahead of the most recent guidance. Electronics, by contrast, saw a -2% organic decline in Q4 as delivery systems and services hit the trough we had expected. Meanwhile, our Semiconductor Materials business kept up its strong performance, helped by robust demand in AI and advanced nodes. Back at the group level, thanks to our strong cash generation, leverage has improved to 1.4x net debt to EBITDA pre, even with continued investment in both CapEx and M&A. As we announced earlier today, at the annual general meeting on April 24th we will propose a stable dividend of EUR 2.20 per share, which would make this the 15th consecutive year with an increasing or a stable dividend. Turning to slide 7, let's examine 2025 through a more strategic lens. Our Life Science business is back in growth, chiefly driven by our Process Solutions. There we are delivering roughly 10% organic growth in 2025 as the market normalized and moved past the de-stocking phase.

Belén Garijo

executive
#5

As you know, this is completely in line with our mid-term guidance and with what we've said before. On strategy, Life Science concentrates on 2 key areas: customer centricity and innovation. To sharpen customer focus, strengthen execution, and improve capital efficiency, we've organized our go-to-market model around the way customers buy. That new model went live successfully in January, and customer feedback has been very, very positive. On strengthening the innovation pipeline in Life Science, let me point to the chromatography business of JSR Life Science and the HUB Organoids acquisitions. Both are excellent examples of how we're reinforcing our portfolio leadership strategy in Life Science. Life science is well-positioned for continued growth, with a stronger customer-facing model and an enhanced product portfolio that support our mid-term growth ambitions. Moving to healthcare, 2025 was a defining year, with rare diseases established as a new strategic pillar, supported by the SpringWorks acquisitions and by securing rights for global commercialization of pimicotinib, which we recently launched in China. We have 3 growth engines — rare diseases, CMN, and fertility — while we'll manage the life cycle challenges for key brands in NNI and oncology. Danny and his team also unveiled plans to replenish the pipeline with an improved risk reward profile, backed by a combination of internal and external innovation.

Belén Garijo

executive
#6

We remain fully committed to keeping healthcare EBITDA pre above 30% and R&D at roughly 20% of sales. Our focus is on delivering growth consistent with the upgraded midterm ambition we have set, with room for additional acceleration over the longer horizon. In electronics, the divestment of Surface Solutions has now been successfully completed, and with that we have become a focused pure-play electronic business. Within Semiconductor Solutions we hold one of the most complete offerings available, which places us squarely at the heart of the artificial intelligence upswing. Demand for materials remains robust, and in SNS we have bottomed out. We are also continuing to shape the portfolio in Optronics. With all of this as a backdrop, we are bullish about the electronics outlook and feel good about growth picking up in the coming quarters. Before I hand things over to Helene, let me quickly highlight a few points on sustainability — I am on slide number eight now. 2025 marks the second year in which we fully apply the European Sustainability Reporting Standards, and I am glad to report that our progress has been excellent. We did not merely hit our 2025 targets; we have in fact already delivered on some of our 2030 environmental ambitions.

Belén Garijo

executive
#7

The clearest case is that we've gone past our 50% reduction goal, reaching a 60% cut in Scope 1 and 2 greenhouse gas emissions against our 2020 baseline. Even as business volumes rise and our portfolio shifts, we work to keep emissions at these low levels moving forward. On greener alternatives, we've already broadened our product portfolio substantially. In Life Science, we posted an impressive 53 year-over-year increase in the count of greener products. We now provide over 5,000 of these products, with combined sales above EUR 300 million, expanding at a CAGR of roughly 30% since 2021. By 2030, we're targeting 10% greener alternatives within our Life Science product portfolio. These accomplishments highlight our dedication to sustainable growth and show that environmental responsibility and business performance go hand in hand. With that, I'll hand things over to Helene for a more detailed review of our financials.

Helene von Roeder

executive
#8

Thanks so much, Belén, and hello everyone joining us. I'm on slide 10 now, and I'll begin by walking through the group's key figures for Q4. Net sales were down 3.1%, landing at EUR 5.249 billion. Organic growth contributed EUR 139 million, but that was more than outweighed by currency headwinds totaling EUR 318 million. Those FX pressures stem from the US dollar along with a range of Asian currencies — among them the Chinese renminbi, Korean won, Indian rupee, and Japanese yen. EBITDA pre fell 3.2% to EUR 1.443 billion, with the margin holding steady at 27.5%, which shows solid operational discipline. EPS pre was EUR 1.88 per share. Operating cash flow rose 4.9%, reaching EUR 1,000,000,291. Working capital was stable versus a year earlier. As of December 31st, net debt stood at EUR 8.6 billion. I'd also like to say a quick word about our reported results, which are on slide 11. EBIT was down EUR 341 million compared with a year ago, largely because of R&D-related impairments in Healthcare. The financial result of -EUR 82 million mirrors higher interest expense and lower interest income after the SpringWorks acquisition. The effective tax rate was 19.1%, which is in fact under our guidance corridor thanks to deferred tax effects.

Helene von Roeder

executive
#9

We anticipate that this effect will return to normal in 2060. Earnings per share as reported were EUR 0.73. If you'll move to slide 12, we'll walk through how each business sector performed. Organic sales growth for the group in Q3 reached 2.6%. The biggest contributor was Life Science, posting organic sales growth of 3.9%, powered by Process Solutions' fourth straight quarter of roughly 10% organic growth. Healthcare rose 3.3% organically, powered by robust expansion in our CM&E franchise, together with contributions from NNI and fertility. Electronics saw an organic decline of 2% stemming from DS&S headwinds. Once again, the Semiconductor Materials business turned in stellar growth in the mid-teens range, picking up market share thanks to new customer qualifications. On earnings, EBITDA pre reached EUR 1.443 billion, an organic increase of 3.1%, powered by all three business sectors. The net portfolio effect proved negligible in Q4, whereas currencies acted as a significant drag of roughly -6% on both group sales and EBITDA pre. In Q4, Life Science grew organically by 3.9%, powered by yet another strong showing from our Process Solutions business, which kept up its momentum, while Science & Lab Solutions was approximately flat. Process Solutions posted organic growth of 9.7%. Order intake stayed strong in Q4, and the book-to-bill ratio remained comfortably above one.

Helene von Roeder

executive
#10

Now moving to Science & Lab Solutions, where organic sales were up 1.2%. That was a slower pace than Q3. Still, it took a hit from the U.S. government shutdown, which weighed on academic and government lab spending, plus a softer market in China. Life Science Services posted an organic sales decline of -8%, which reflects high comps and fluctuating demand at key customers. Our R&D ratio came in slightly higher, in line with our ambition of reaching roughly 5% of sales in the midterm. EBITDA pre rose 2.5% organically. That implies a margin 40 basis points lower year-on-year, since operating leverage was more than offset by FX headwinds and start-up costs for site expansions. As we move into Q1, our reporting structure will be updated to align with the new go-to-market strategy. As a reminder, Process Solutions will remain unchanged. Advanced Solutions will comprise our businesses in lab water, diagnostics-related materials, biomonitoring, contract testing, as well as development and manufacturing services. Our third franchise, Discovery Solutions, will combine our chemical and biology operations. As detailed at our last CMD, this new organizational setup will sharpen our strategic focus on customers and operational efficiency. Turning to Healthcare on slide 14. Healthcare delivered a solid organic sales growth of 3.3% in Q4, that was mainly driven by our CM&E franchise, up 7% organically with strong performance across all therapeutic areas.

Helene von Roeder

executive
#11

Organic growth in fertility came to 3%, with the main driver being Pergoveris, which posted a 22% gain and keeps performing strongly. Approval for Pergoveris in China was secured recently, and we're still working toward a U.S. launch in H2 '26. Within our NNI franchise, sales rose 3% organically. MAVENCLAD had another robust quarter, rising 16% organically, and the first generics launch in the U.S. in December had only a minor effect. As expected, oncology saw a moderate organic sales decline. A major factor there is tougher competition for ERBITUX in China from non-comparable biologics. Beyond the solid organic performance, consolidating SpringWorks gave us a significant portfolio effect of 5 percentage points. Sales for our newly established rare disease franchise were 20% higher quarter over quarter. Stocking effects contributed in part, which essentially accounted for their outperformance versus guidance, and consequently we anticipate OGSIVEO sales will be modestly down quarter-over-quarter in Q1. On the pipeline side, pimicotinib recently received its first regulatory approval in China, arriving well ahead of schedule. We anticipate minor sales contributions over the coming months and are working toward NRDL inclusion as of 2027.

Helene von Roeder

executive
#12

Regarding the U.S., we expect a decision from the FDA near the end of the year. We're also getting ready to launch two phase III trials during this year. The first is enpatoran for lupus rash, and the second is PreCim TCT in third line colorectal cancer. On the earnings side, EBITDA pre came in at EUR 683 million for Q4, at a 31.2% margin as expected, which reflects normalized R&D now aligned with our target of roughly 20% of sales. As we look toward Q1, keep in mind that we foresee an organic sales decline closer to the lower end of our full-year guidance, with every franchise projected to be down year-on-year due to a combination of factors, among them tough comps and phasing. Danny will gladly give more detail if that's helpful. Let's turn to Electronics on slide 15. Sales were down 2% organically in Q4. Semi Materials posted solid double-digit growth. Semiconductor Solutions fell 4% organically, since the strength in Semi Materials was not enough to fully offset the expected drop in delivery systems and services. Digging a little further into Semiconductor Materials, demand for advanced nodes keeps fueling growth for the 8th quarter in a row, averaging low teens growth. For the full year, Semiconductor Materials rose in the high single digits.

Helene von Roeder

executive
#13

This mirrors favorable trends in AI-driven 3D demand, along with strength in Asia for specialty and mature nodes. In DSMS, the quarter came in as we had expected. As Kai pointed out and we anticipated on our Q3 call, we called out roughly EUR 100 million of downside in DSMS for Q4, and that is indeed what happened. Our view is that DSMS hit bottom in Q4 and will steady from here. Our Optronics business posted moderate organic growth of 5%, helped by a solid quarter in our traditional applications. EBITDA pre-margin rose 250 basis points year-over-year to 27.2%, driven mainly by accretion from the Surface Solutions divestment and continued cost dis-discipline in the business. The high twenties margin now reflects the pure-play electronics business, clean of Surface Solutions. Let me also briefly touch on our balance sheet and cash flow statement. As you can see on slide 16, our balance sheet at year end of 2025 shrank by EUR 100 million year-over-year. Let's look a bit closer at the asset side. Cash and cash equivalent grew by about EUR 200 million, mainly reflecting net effects from the US dollar bond issuance tied to the SpringWorks acquisition and the divestment of Surface Solutions.

Helene von Roeder

executive
#14

Receivables held steady, whereas inventories rose by roughly EUR 100 million. Intangible assets were up by approximately EUR 100 million net, largely because of the SpringWorks PPA. Property, plant, and equipment fell by around EUR 100 million, chiefly as a result of FX. And finally, other assets declined by about EUR 500 million, primarily driven by the Surface Solutions divestment. Now let's move to the liability side. Financial debt rose by EUR 1.7 billion, which reflects funding for the SpringWorks deal. Pension provisions dropped by EUR 400 million, mainly on actuarial gains. Payables and other liabilities stayed roughly flat. Net equity fell by EUR 1.3 billion, driven primarily by FX. So in summary, our equity ratio came down from 58% to 56% at year end. Moving to cash flow on slide 17. Operating cash flow rose to EUR 1.291 billion in Q4 2025, compared with EUR 1.231 billion in Q4 of last year. Profit after tax was lower because of impairments in Healthcare and other non-cash portfolio actions, including the divestment of CDMO activities in Martillac, France. D&A is up significantly, which reflects the non-cash character of the impairment and portfolio actions. Movements in other balance sheet items were comparable to the prior year period.

Helene von Roeder

executive
#15

So with that said, I'm very happy to pass things over to Kai, and he'll walk you through the financial guidance we're giving for 2026.

Kai Beckmann

executive
#16

Thank you, Helene. Before I get into the 2026 guidance, I'd like to pause and express my appreciation for Belén's exceptional leadership. I also want to recognize the successful years we've had with her at the helm. Belén, the support you've given throughout the CEO transition has been invaluable, making possible a smooth and effective handover just a few weeks from now. On behalf of the team and the executive board, thank you, Belén, for laying a strong foundation for our future. I'm looking forward to building on the successes we've achieved together. Let me now move to the outlook for 2026. As a quick reminder, much like last year, we are sharing quantitative targets for net sales and EBITDA pre alongside our full-year results. Moreover, for the first time, we're pleased to offer an outlook for EPS pre together with our full-year guidance. Before we go into the details, there are two key assumptions to keep in mind. We assume no MAVENCLAD sales in the U.S. as of March 2026. Our guidance also does not reflect the potential launch of Pegvuregis in the U.S. We forecast group net sales in the range of EUR 20 billion-EUR 21.1 billion.

Kai Beckmann

executive
#17

That gives us organic sales movement between -1% and +2%. For EBITDA pre, our outlook is EUR 5.5 billion to EUR 6 billion. That works out to organic growth spanning -4% to +1%. Regarding currencies, keep in mind that for Q1 we anticipate a currency headwind that is disproportionate compared with our full-year FX guidance. As you'll see, the midpoint implied by our guidance plainly reaffirms what we indicated early on: EBITDA pre margins of around 28% at group level. To wrap up the group picture, that converts to an EPS pre range of EUR 7.10 to EUR 8. For a bit more detail, let's turn to slide 20. Beginning with Life Science, we reaffirm mid-single digit organic sales growth. That aligns with the projections Jean-Charles gave at our CMD last October. Our assumption mirrors sustained strong performance in our Process Solutions business, and across Advanced and Discovery Solutions we expect biotech funding to improve gradually and academic research to stabilize. Beyond that, we confront a shifting market environment in China. Turning to Healthcare. A difficult year lies ahead of us amid life cycle challenges for key brands, MAVENCLAD in particular. We anticipate growth in the rest of the portfolio, including CM&E, fertility and, above all, rare diseases, which will become organic in the second half.

Kai Beckmann

executive
#18

Danny and his team are still fully dedicated to keeping margins above 30%, which is what the guidance shows. In Electronics, we expect our Semiconductor Materials business to keep growing strongly, while our DS&S business levels off from here on. One-timers in electronics will add to mid-20% growth in EBITDA pre. On one side, there's the negative EUR 51 million from 2025; on the other, 2026 brings a positive contribution from OLED IP sales plus supplier compensation, together roughly EUR 60 million in 2026. Setting those one-timers aside, the underlying business is showing attractive operational leverage. Before Q&A, we're joined by Benjamin Hein, who will take over from me as CEO of Electronics. Ben and I have collaborated closely for many years. He was central to shaping the Electronics strategy and to transforming performance materials into a focused semiconductor business. Ben is with us today from Arizona, where he's meeting customers. Ben, wonderful to have you here for a quick introduction.

Benjamin Hein

executive
#19

Thanks, Kai, and greetings to all of you from my end here in sunny Arizona. First, I want to express appreciation to the Merck family for the confidence they have shown in me, and to Kai for the leadership he provided in building the Electronics business as it stands today. During recent years, Kai drove the transformation that produced a pure play business resting on an exceptionally solid base. For anyone here who may not know me well yet, I have spent 13 years at Merck KGaA, Darmstadt, Germany, holding leadership positions spanning group strategy, Electronics and Life Science. A central thread in my experience has been leading teams and delivering alongside our customers in Taiwan and Southeast Asia for Electronics, and most recently in Boston, Massachusetts, for Life Science. That is how we support customers now. AI going forward will demand stronger performance from the chip. That calls for novel materials and chemistries, new connectivity such as silicon photonics, and complex scaled architecture. Bringing together materials, data and control is going to matter more than it ever has. In this position, strengthening what we do well and pushing harder on execution matters greatly to me. I will keep building on that solid foundation, move faster together with our customers, and make sure we have operational precision while co-developing innovation at speed.

Benjamin Hein

executive
#20

I'm really eager to connect with a lot of you sometime soon. So with that said, I'll hand things back over to you, Florian.

Florian Schroeder

executive
#21

Thanks a lot, Ben, for spending time with us today. Next up is the question-and-answer portion of our call, and after that Belén will share a few special closing remarks. Sarah, I'll pass things to you now so you can get the Q&A session started.

Operator

operator
#22

Thanks. We’re moving into the Q&A part now. If you’d like to ask our speakers something, press star one one on your phone keypad at this point to join the queue. After your name is called, you’ll be able to pose your question. Today, if you’re on speaker equipment, kindly pick up the handset before you make your selection. Just a moment, please, while we take the first question. The first question comes from Richard Vosser at J.P. Morgan. Please go ahead.

Richard Vosser

analyst
#23

Hello, and thank you for taking my questions. There are two, please. The first concerns electronics. Looking at a few of your customers, they are raising CapEx once more, and you pointed to DS&S having bottomed out, but I wanted to ask whether you could provide a little additional detail on how things look for DS&S and for the Semiconductor Materials business. You referenced DS&S stabilizing. What is the reason we should not expect that portion of the business to improve in 2026? On the materials business, I am curious about how durable that robust double digit growth at advanced nodes is, and what is happening regarding some of the older nodes catching up. Then the second question is on Process Solutions. You know, you mentioned the strong order book. Given that strong order book, I wanted to ask about the visibility you have into 26, and whether we might perhaps even expect growth in 26 that is stronger than the 10% you delivered in 2025. Thanks very much.

Kai Beckmann

executive
#24

Richard, I’ll take the electronics question. Regarding DS&S, as our customers’ CapEx ramp-up is planned, after the stabilization in 2026 we will see ourselves heading toward the midterm guide going forward. That’s going to take some time, and keep in mind that we’re still up against some project ramp-downs from the first half of last year. Those comparisons are still something we have to get past for that stabilization. Second, on the materials side, our customers are working on debottlenecking their capacity for AI and advanced nodes, and that is continuing right now as we speak. That will give us momentum that carries well into 2026 — pretty good growth for the materials business, for semi materials.

Jean-Charles Wirth

executive
#25

Hi, Richard. This is Jean-Charles. I’ll take the second question about Process Solutions. First, we don’t give guidance by BU, but I’d like to share a few thoughts. One, we still see the bioprocessing market as structurally attractive, with midterm growth in the 9%-10% range. As for 2025, yes, we had a solid performance, with organic growth of roughly 10% for the full year. We have a very clear view of our order book. Our order book looks solid. Maybe to address one more question, our book-to-bill ratio remains comfortably above 1. On that basis, and with ongoing exchanges with our customers, we reaffirm our 2026 guidance for Process Solutions, and your mission is to go around 10%. I’d like to highlight one point. When we say around 10%, you should assume some quarters will go 8, some quarters will go 12. Overall, we are confident, very confident in Process Solutions to go around 10% for 2026.

Richard Vosser

analyst
#26

Thanks a lot.

Operator

operator
#27

Thanks. We're ready for the next question now. It comes from Peter Verdult at BNP Paribas. You have the floor.

Peter Verdult

analyst
#28

Thanks. Peter Verdult here from BNP. I've got two quick questions for Kai and one for Danny. Kai, when are you planning to lay out the go-forward strategy for Merck? I realize it won't be a revolution, but when should we expect to hear from you? Will that be at the CMD in October, or might it come sooner? Staying on the current business, Electronics, just on smart glasses — I realize this is probably relatively immaterial at the moment. My assumption is that the business is under $50 million, but it's clearly going to be a huge growth area. Can you help us better understand Merck's competitive advantage there, and how material the current business is, either in terms of revenues or margins? Danny, on pipeline prioritization and replenishment, it's good to see the DVR portfolio efforts terminated. I just wanted to better understand whether phase III CEACAM5 is contingent on securing a partner, or whether Merck is now willing to go solo? And could you give us a bit of a temperature check on the M&A environment? I know you won't talk about specific assets, but you've clearly articulated a desire to accelerate the transformation toward rare.

Peter Verdult

analyst
#29

How would you describe the current environment for doing that—good, bad, or ugly? Thanks.

Kai Beckmann

executive
#30

Thanks very much, Peter, for those 2 questions. On the first one, perhaps Belén and I should first wrap up on the transformation and the transition, and then, once we are sitting together after May 1st, we will get back to all of you and share the plans going forward. It is far too early to make any projections today. Second, on ARVR, you are correct that with the quite low-tech solution currently seen in the market, our business is quite low on this one. Assuming we will see more implementation of higher-end glasses with a higher field of view and higher color intensity contrast, that is where the technologies currently being developed will then have an opportunity. It depends, of course, on our customers' roadmap, and again, it is far too early to speculate on that. As we said during the CMD at the midterm guidance, none of that is included in our midterm guidance. It is not yet as visible as we would need it to be for including it in our midterm guidance.

Operator

operator
#31

Thanks.

Danny Bar-Zohar

executive
#32

Okay, Peter — thanks for getting that in so fast. Danny, apologies for how deep my voice sounds. On the pipeline side, as you'll recall, there's a phase III trial already running with cladribine tablets in generalized myasthenia gravis. As you know, recruitment is going very well, in our expectation, and we expect topline results around 2028. Beyond that, this year we're launching 2 studies — 2 phase III studies, the twin studies — with enpatoran TLR7/8 in lupus rash. Enrollment should begin within the next couple of months. Unless I'm mistaken, they're listed on ClinicalTrials.gov. You brought up CEACAM5 precemtabart tocentecan. Given what I'd call very encouraging results from the phase I-B and the expansion cohorts, we're kicking off a trial in 3rd line colorectal within the next few months. That's the plan. The protocol has been aligned with all regulatory authorities. On partnering CEACAM5: yes, we've said that if this program is going to be expanded further beyond third line colorectal cancer, we would really like to partner it, you know, to share the cost and the risk. Partnering discussions are currently ongoing with potential partners. We're also looking for, or waiting on, additional combination data to come in earlier lines that will dictate the rest of the clinical development program.

Danny Bar-Zohar

executive
#33

As I mentioned during Capital Markets Day, and David also referenced this, we're heading toward populations that are more homogeneous from a biology standpoint. You're less likely to see us entering neurodegeneration over the next couple of years, or going after very large-population solid tumors. Homogeneous populations can be diseases that are epidemiologically rare, and that's a major focus for us. Pimicotinib, GOMEKLI, OGSIVEO, plus other smaller assets currently in the pipeline stemming from internal innovation. Myasthenia gravis is itself a rare disease, so we're already present there. We'll keep expanding in that area. Regarding your question about the fertile ground out there, we're highly encouraged, and we're extremely active when it comes to seeking the next opportunities. We need to supplement the pipeline primarily around the peri-poc and deliver on the phase III programs, which are very exciting.

Peter Verdult

analyst
#34

Thank you.

Operator

operator
#35

Thanks. We’ll move on to the next question now. It comes from Matthew Weston at UBS. Go ahead, please.

Matthew Weston

analyst
#36

Thank you so much. Before I begin, Belén, congratulations on reaching the end of an era at Merck, and Kai, best of luck in the new role. Belén, I look forward to seeing you in your new position. On to my question — I have 2, and both concern guidance. The caveats attached to the 2026 guidance don't make sense to me. A generic erosion reaching 0 within 6 months is something I don't believe I've ever witnessed, and a company excluding a pipeline opportunity unless a regulator has raised an issue is likewise something I don't think I've ever seen. Could you walk us through the MAVENCLAD decision, and can you give us reassurance that everything is fine with Pergoveris at FDA? Then a specific question for Jean-Charles about Life Science guidance. If you have high confidence in the bioprocess growth you described when answering Richard's question, how do we arrive at the 3% organic life science growth figure at the bottom end of the 26 growth range?

Belén Garijo

executive
#37

Thanks for the kind words, Matthew. On your first question, I'll ask Kai to cover the 2026 guidance, and Danny will join in as well.

Kai Beckmann

executive
#38

Matthew, I appreciate your kind words, and I'll take up your question about the guidance. I'll begin, and then Danny will provide a few further insights regarding the products you brought up. Let me first touch on the reasoning behind our approach, which I think is fairly clear-cut. As for MAVENCLAD, we won't make guesses about when generics might come in or how they'll behave in the market. To be honest, speculating offers us very little benefit. So, on this item, we've taken a more cautious stance by laying out our assumptions explicitly. Naturally, we'll continue to update you throughout the year. You can be sure we'll handle the decline with great care, always aiming to maximize returns for shareholders while putting patient needs first. Much the same applies to Pergoveris: we're pushing the filing under the CNPV forward as swiftly and thoroughly as we can. As Helena noted earlier, we're getting ready to launch in the second half of the year. That said, the final call on whether Pergoveris gets approved lies outside our hands, so we've decided to leave any potential sales out of our guidance. Danny, perhaps you'd like to add a little more detail on that.

Danny Bar-Zohar

executive
#39

I completely agree with what you've said. Matthew, just a bit more detail on MAVENCLAD. As you might recall, we submitted the petition to the CAFC for a panel rehearing at the very end of November last year. That petition was denied at the end of January. Given that ruling, we anticipate that generic companies will ask the district court to lift their 30-month stays where applicable. As of today, 1 generic version of MAVENCLAD has received final FDA approval. That approval came at the end of November, and it has entered the U.S. market. What I can share is that already in December, we're seeing a volume impact from that 1 generic. Another generic received tentative FDA approval in early December. To the best of our knowledge, 3 additional companies are also working on developing MAVENCLAD generics. So you're right. Generic erosion curves do exist. But the unknown entry date of the second generic, along with how the others we know are trying to get in will play out, makes predicting sales very difficult for us. On top of that, you should also factor in the unknowns of how those erosion curves will behave in year one and year two, given the very special dosing regimen for MAVENCLAD.

Danny Bar-Zohar

executive
#40

That being said, yes, you could view that as conservative, and our guidance excludes U.S. sales of MAVENCLAD as of March. On the question about Pergoveris in the U.S.: under the Commissioner's National Priority Voucher process, we filed part 1 of the Pergoveris application at the end of November. At present we're in a rolling submission mode and getting part 2 ready. The clock begins running once part 2 has been submitted. Now, as we've mentioned, the Pergoveris submission rests — and I've said this — on a great deal of legacy data. A great deal of legacy data. Our data are extensive. Although this is, you know, not our first filing with the regulator, the CNPV procedure is fairly new. I want to make sure the FDA has everything required for an approval. We have this 1 shot, and we wanna get it right. Now, we are diligently working through adaptations from data gathered primarily to satisfy ex-U.S. authorities to the FDA, and we're doing so in close collaboration with the FDA. That means there's some uncertainty regarding the exact timeline for submitting the second part. Of course, we'll keep you updated.

Danny Bar-Zohar

executive
#41

Like Kai and Helena said, we are still targeting a possible launch during this year's second half. Now, on the size of the opportunity — how much should be forecast — as I said earlier, that hinges heavily on timing first of all, and after that on the label, so giving further specifics at this stage would be premature. Beyond that, you also need to keep in mind the channel and access discussions with payers. There are plenty of unknowns, and the biggest one is in fact the timing, plus the fact that the submission is not yet finalized. You can be sure we intend to get the product to patients as quickly as we can. As we have stated, second half 2026.

Jean-Charles Wirth

executive
#42

Richard here, Jean-Charles speaking. Regarding your question about Life Science guidance, I'll begin with the fact that we're reaffirming what we first shared at Capital Market Day, when we mentioned mid-single-digit organic growth for Life Science. If you peel the onion, that breaks down across the three business units. Let me give you some hint. For Process Solutions, we confirm that we're marching toward organic growth of around 10%. As I said earlier today on the call, we have a very clear view of our order book. Our book-to-bill ratio sits comfortably above one, and we keep having ongoing clear discussion communication with our key customers. On Process Solutions, we're very confident. From an assumption standpoint in Advanced Solutions, we expect organic growth this year toward the lower end of our midterm guidance, and at present we assume that the QC testing business, namely bio monitoring, will be a key driver of that growth. As for Discovery Solutions segments, we expect performance to be flattish as headwinds persist, such as academia and biotech funding, China and the macroeconomic factor, including tariff. That's one part of the answer. To be clear on your question about the 3% organic growth, which will be at the low end of our guidance.

Jean-Charles Wirth

executive
#43

Should we land at the bottom of the range we've guided to, the non-Process Solutions units would be the reason — specifically Advanced Solutions and Discovery Solutions. The main challenges we see are China, NIH funding, biotech funding, and, as you might say, wider macroeconomic forces.

Matthew Weston

analyst
#44

Appreciate it, everyone. That's very clear.

Operator

operator
#45

Thanks. We’re ready for the next question now. It comes from Sachin Jain at Bank of America. Go ahead, please.

Sachin Jain

analyst
#46

Hello, and thank you for taking my questions. I suppose there are two for Dan, if I may. Just building on the earlier question about Pergoveris, I'd like a clearer picture from your standpoint: at what point would you be sufficiently at ease to include it and provide guidance? Would that be once part two has been submitted, or would full approval be necessary? I realize you'd prefer to see the label, but maybe you could remind us, for our benefit, where you're observing differentiation for this product in markets outside the US, and how share and uptake look, so we can start considering how best to model the US. The second one concerns the 2 SpringWorks assets.

Danny Bar-Zohar

executive
#47

Could you walk us through the most recent developments on the two launches and how we ought to frame progress across this year? Is there anything worth flagging regarding the geographic breakdown of the launch? And now that the Immunome data are in hand, has your view shifted at all on that program as a possible rival looking ahead to 2027? Thank you very much, Sachin, for those questions. On Pergoveris, as I mentioned earlier, the whole CNPV process is just as unfamiliar to us as it is to the FDA. We have to keep that in mind, and I suspect a number of other companies receiving these vouchers are likewise proceeding with some caution. We get one shot here. When will it arrive? As we've stated, our assumption, our aim, and our goal, together with the FDA, is to have it in the second half of this year. On the rolling submission, part one went in during November. We're actually filing smaller pieces along the way. We remain in continuous dialogue. There is a challenge, I'd say, in adapting fairly old legacy data from Europe to what the FDA requires. That could take time. At first, we believed we would finish that in March.

Danny Bar-Zohar

executive
#48

My expectation is that it will slip past March so that it can be done properly. That's just the nature of—I'd say there's a bit of uncertainty around the approval timelines. The 60 days the FDA allows only begin once that second part has been submitted. On the label, I don't want to say too much, because we're in the middle of a review with the FDA right now, and that's not something we normally do. It hinges on the eligible patient population and on how the need for the therapy gets defined—whether that's by hormone levels or by clinical judgment—and I'll leave it at that. That's another unknown. We're making very good progress, but we'll keep it at that. As for SpringWorks, broadly speaking, I stay very confident in what both products can do, yeah. With OGSIVEO, we positioned it as having around blockbuster potential, and GOMEKLI as having near blockbuster potential. On GOMEKLI, the uptake encourages us, with sales up 35% quarter-over-quarter in Q4. We're seeing positive uptake in both the pediatric and adult populations, which matters a great deal to us. We're seeing 90% penetration in centers of excellence while also successfully reaching into non-centers of excellence.

Danny Bar-Zohar

executive
#49

As a quick reminder, KOSELUGO is in the same class as this one and is fairly well established. Also, the early signals from GOMEKLI's European launch look encouraging — it went out in Germany and Austria during Q4, with additional launches country by country slated for Europe over the coming months and quarters. Turning to OGSIVEO, I'm just as happy with how OGSIVEO is being taken up, starting with Europe, since I brought Europe up earlier. That drug came to Germany in the middle of Q4, and to Austria as well, and the launch looks very strong at the moment — quite comparable to GOMEKLI. In the U.S., as I've mentioned the last couple of times we've spoken, OGSIVEO is now in the second phase of its launch. We're moving away from what you might call the warehoused patients and toward finding those under active surveillance who ought to receive systemic treatment. That patient pool is a sizable one. More than 20,000 patients in the U.S. alone carry a diagnosis, and of those, you could say 20%-30% sit under this active surveillance. We're deploying plenty of tools, AI among them, to find these patients, especially at the community level. They aren't always lingering at the center of excellence anymore.

Danny Bar-Zohar

executive
#50

Our messaging to patients and healthcare professionals is also getting more targeted now. Our focus is on retaining as many patients as possible by drawing on the fairly large body of long-term data we have available, and by educating people on managing adverse events through dose modifications. When it comes to the ability to modify the dose, our formulation, the dose and the dose strength give us an edge. That matters a great deal. It also helps improve compliance and persistence. Desmoid tumors are a chronic disease, and the patient, the physician and, to some degree, the drug have to be managed together—or dance together with the drug over the long term. This isn't only about handling adverse events. These tumors act differently from malignant ones. I'd rather not reveal precisely what we know about patient dynamics, since we will face competition in the class, but my suspicion is that the same dynamics will apply to the competition too. Yes, OGSIVEO is currently in a stretch of slower growth. I also expect OGSIVEO sales in the first quarter of 2026 to be lower than in Q4. That said, seasonality is the main reason for this.

Danny Bar-Zohar

executive
#51

We did see some stocking in Q4 ahead of the expected WAC increase, and that's normal. As we told you, we've actually kept that stocking to a minimum, and it's far less pronounced than what you saw with SpringWorks precisely a year ago, in the transition from Q4 2024 to Q1 2025. The key point is that underlying demand keeps rising. We saw that in Q4 versus Q3, and we expect new patient starts in Q1 to be higher than in Q4. We stay confident about that. On the Immunome data, I also said that the CMD for every one of the rare tumors we have, or either have or will have, faces strong in-class competition. We're aware of that, and AL102 has been taken very seriously from the get-go. With all of the fine attempts at indirect comparisons, this is the same class. The numerical differences in response rates are, of course, there, but the question is what they mean for a patient. As I said earlier, the patient has to feel comfortable with a drug over the long term. It's a nasty disease, but it isn't a malignant one. The treatment should be long-term, as I said, and need to.

Danny Bar-Zohar

executive
#52

We really need to see the data on the things that matter to patients as well. Pain, quality of life, onset of effect. That data we haven't seen. When it comes to toxicity, this was also brought up from time to time, each drug has to manage patients on the tolerability side. The most bothersome tolerability issue is the GI effect. On this side, as expected, both drugs have quite, I would say, identical rates. Here comes how these patients are handled, kept, dose-adjusted. As I said before, the BID dosing that we have and the different dose strengths of OGSIVEO that we have are actually a potential advantage here, and we know that. We know that because I am personally talking with a lot of prescribers. More than 1,300 prescribers have already prescribed OGSIVEO — we have touched them. This is what they are telling us. This flexibility is important. On ovarian toxicity, you know, it's on target. We knew that. It's also important to see how they reported their numbers in terms of apples to apples. OGSIVEO will have been in the market for almost 3 years when AL102 is launched. That's quite a long time for same line, same class competition.

Danny Bar-Zohar

executive
#53

Our long-term dataset is both the widest and the deepest available. What it shows is growing efficacy, along with impacts on quality of life that are very robust, and no fresh safety signals have emerged. AL102 is a credible rival. We have confidence in OGSIVEO's strength and in what it can achieve.

Sachin Jain

analyst
#54

Thank you.

Operator

operator
#55

Thanks. We’re moving on to the next question now. Theodora Rowe Beadl from Goldman Sachs is on the line. Go ahead, please.

Theodora Rowe Beadl

analyst
#56

Hello, and thank you for taking my questions. First, it appears that the DDR portfolio has been removed from your pipeline chart. What prompted the decision to discontinue that program, and how do you intend to reinvest the R&D spending that this frees up? Second, what are your expectations for the pimicotinib launch, both worldwide and in the US, assuming it gets approved? Thank you.

Danny Bar-Zohar

executive
#57

Thank you. Kai, I'll handle the questions. Starting with the DDR. As was rightly noted, the key assets in that portfolio were tuvusertib, the ATR inhibitor, and the PARP1-selective compound we in-licensed from Hengrui. Both were removed from the pipeline, each on the basis of data — data-driven decisions. We conducted combination trials, especially with other DDR agents in selected populations alongside chemotherapy, attempting to address all of these questions. I have to say we answered them fairly quickly and at fairly low cost. If you look at other companies working on DDR in this space, I'm genuinely proud of the R&D organization that managed to resolve all of these questions very fast and very clearly. These have been taken out of the pipeline. Yes, on paper, R&D resources have been freed up, so to speak, but they're being put to good use ramping up the phase III programs. Tadruventin in myasthenia gravis, pritelivit, the CEACAM5 in colorectal cancer, two studies with enpatoran, phase III studies. I'd say our hands are full, and of course we're keeping our R&D spend around 20%, and we'll continue moving forward that way. Yeah. Turning to the pimicotinib launch.

Danny Bar-Zohar

executive
#58

As Belén said, the drug got its first approval in China, considerably earlier than expected, and that makes us very pleased. It will be launched in the private market in, I'd estimate, a few weeks from today. We're quite enthusiastic about what this drug could do in China. Right now we're in discussions — an NRDL discussion — so as to secure the price in China, though that won't take effect until 2027. We filed with the FDA. The file has been accepted, meaning the clock is now running, meaning we have a PDUFA date, an action date, near November of this year. Keep watching for that. We filed in Europe as well. On the whole, we've stated that pimicotinib's potential in TGCT will come in at roughly near half blockbuster, I'd say.

Operator

operator
#59

Thanks. We'll take the next question now, and it comes from Oliver Metzger at Oddo BHF. Go right ahead.

Oliver Metzger

analyst
#60

Good afternoon, and thank you for taking my questions. My first question concerns the Electronics guidance. You're targeting organic growth of 3%-7% for 2026. I'd just like to grasp the dynamics more thoroughly. On one side, you have Semiconductor Materials, which is performing very well. You mentioned above 10%, or even 15% in Q4. DS&S ought to stabilize, say, in H1, and then, on easier comps, turn positive in H2. Optronics, at a single-digit range, doesn't appear ambitious. In particular, looking at the lower end, it seems to involve a good deal of safety caution, yet even at the high end, it appears you're, let's say, factoring in more uncertainties. A comment on that would be great. My second question is very quick, on Process Solutions. You made only a brief remark about equipment demand. Could you tell us how you see demand for equipment developing and when we should expect a normalization of that? Thank you.

Kai Beckmann

executive
#61

Oliver, I’ll start with the Electronics question. If you consider that Semiconductor Materials accounts for 66% of our business, then it’s roughly 15 in DS&S and approximately the remaining 20% in Optronics. As we’ve said, Optronics is about stable, DS&S is about stable, and the materials business is at high single-digit. That brings you to the midpoint of our guidance. What sort of puts us toward the lower end of the guidance is that the current constraints come from high memory prices, which are limiting consumer behavior in consumer electronics. That’s the optionality pushing us toward the lower end of the guidance, while our customers’ efforts at debottlenecking advanced node capacity and AI-related capacity would give us the chance to move toward the higher end of the guidance. That provides the framework for the guidance, and that should let you do the math as per our CMD and Q3 communication last year.

Jean-Charles Wirth

executive
#62

Hi, Oliver. This is Jean-Charles. Regarding your question about Process Solutions equipment, it's worth remembering that consumables make up over 90% of our portfolio, so our visibility into and exposure to equipment is quite limited.

Oliver Metzger

analyst
#63

Thanks.

Operator

operator
#64

Thanks. We’re ready for the next question now. It comes from Charles Pitman King at Barclays. Go ahead, please.

Charles Pitman-King

analyst
#65

Hi, guys. I have 2 questions for Jean-Charles, please. First, just on life science. I know we've sort of been warning about possible downside drivers, but I was wondering a bit more about the potential upside drivers. I mean, given that M&A picked up in 2H 2025 and we saw a record year for China in licensing, I'm just wondering how your RFP discussions are beginning to evolve. Are you seeing any possible uptick in interest for advanced therapy development, acknowledging the NIH funding and macro issue, as you mentioned? Just how are you thinking about the potential for U.S. onshoring, given recent U.S. peers have been pointing to a kind of 2027 to 2028 timeframe, just in terms of your midterm outlook? Just a second point. Following your strategic review of the Life Science business that gave us these new divisions, I'm just wondering if there's any follow-up or further thoughts on the potential future of your CDMO offering within that. Thank you.

Jean-Charles Wirth

executive
#66

Thank you. I appreciate the question. I'll begin with the second one regarding CDMO. If we take a step back for a moment and look at 2025: we noted that the LSS business saw a decline in 2025, and that was primarily caused by customer phasing as well as, let's say, reduced funding in biotech, which has an impact on a great deal of our CDMO business. Turning to the CDMO business, you're correct. We said at the capital market day that we are steering through the complexity of the CDMO markets with a strategic approach for us that keeps our focus on customer needs and customer expectation. I also said that at present we are reviewing our CDMO business so that these businesses line up with our mission and with our existing portfolio. To accomplish this, we have put in place a very robust decision-making framework, so as to assess the market, assess our operational excellence, and assess financial ambition and implication. That framework makes sure our strategic initiatives stay close to our commitments as a customer-centric organization. At this point, we are making progress. Paolo Carli, the Head of Advanced Solutions, is working on this assessment, and be sure and rest assured that once we are ready, we will return with further information on our CDMO business. On the uptick and onshoring, as I said earlier in response to the question, the majority of our Process Solutions portfolio is consumable-related.

Jean-Charles Wirth

executive
#67

In the near term—2026 and 2027—we don't anticipate significant upside tied to onshoring in the U.S., for instance. Perhaps we'll see some upside in 2027 and 2028, but for 2026, no upside from onshoring is expected. Again, that ties back to our portfolio, much of which relates to consumables.

Charles Pitman-King

analyst
#68

To follow up on that, when it comes to your RFP conversations around advanced therapies, is anything shifting as a result of the recent rise in M&A or licensing activity? Have your discussions changed at all?

Jean-Charles Wirth

executive
#69

At this point, nothing is changing.

Charles Pitman-King

analyst
#70

Thanks a lot.

Jean-Charles Wirth

executive
#71

I appreciate that.

Operator

operator
#72

Thank you. We’re ready for the next question now. Falko Friedrichs of Deutsche Bank is on the line. Please go ahead.

Falko Friedrichs

analyst
#73

Thank you. I have two questions, please. First, could you expand on why Q1 is forecast to land at the low end of the full-year guidance? Should we look for an improvement in Q2, or would you characterize the year as more back-end loaded when it comes to growth and margins? Second, what growth do you anticipate from MAVENCLAD outside the US in 2026? Thank you.

Helene von Roeder

executive
#74

Falco, regarding the low end of the guidance for that item, the key point is what Danny just detailed — namely that we anticipate weaker sales in Q1, particularly in healthcare. I believe he covered all the relevant points on that. Another factor you should keep in mind is that FX shows essentially the largest delta between Q1 25 and Q1 26, since that quarter saw the biggest market moves in FX. Those are the two reasons I think you ought to focus on. I'll hand it over to Danny.

Danny Bar-Zohar

executive
#75

Yeah.

Helene von Roeder

executive
#76

With respect to MAVENCLAD.

Danny Bar-Zohar

executive
#77

Thank you. Thank you, Helene. As you mentioned, we do anticipate Q1 healthcare sales dropping—I'd say toward the lower end of our full-year guidance range of -7% to -4%—and in fact every franchise will be down versus a year ago, for a variety of reasons that include phasing as well as tough comps. Let's go through them one at a time. Beginning with CM&E: for the full year, we expect results consistent with our midterm guidance of mid-single digit organic growth. Q1 should be moderately lower, with a decline of roughly low to mid-single digits. The primary driver here is a very demanding comparison. I'm not sure you recall, but Q1 2025 delivered 11% growth. Beyond that, some business may move from Q1 into Q2 of this year because of certain geopolitical circumstances, which you know about in the Middle East. Turning to fertility: in fertility, we anticipate low single digit organic growth for the full year, once again excluding the potential for Pergoveris in the U.S. That sits under the mid-single digits we anticipate over the midterm, largely because of the near-term headwinds that remain for GONAL-f in the U.S. Broadly speaking, these headwinds consist of a substantial price reduction for GONAL-f in Q2 of last year, which will only be annualized this year—fully annualized during this year.

Danny Bar-Zohar

executive
#78

You're going to see an impact in Q1. We've got a lower inventory valuation for GONAL-f given the direct-to-patient model that we agreed with the White House. We'll have the initial effect of the MFN. On the oncology side, and for NNI, we expect both franchises to decline — and I'd say significantly — in 2026, because of life cycle challenges affecting the key brands. Under our guidance, which assumes no MAVENCLAD sales in the U.S. as of March, the NNI decline should be, I would say, substantially more pronounced than oncology's. In Q1, though, the decline could be, I'd say, more similar — likely around slightly higher than 10% for both franchises. That said, you know, this ties closely to what I said at the Capital Markets Day. What you can expect from us is the highest degree of clarity and transparency about what's coming. We keep our full enthusiasm for the growth of OGSIVEO, GOMEKLI, pimi, Pergoveris, and of course, the CM&E. As for your question about MAVENCLAD's potential outside the U.S., you saw double-digit growth in 2025, both in Q4 and for the full year. This is the most prescribed oral high efficacy drug.

Danny Bar-Zohar

executive
#79

We anticipate ongoing, quite robust expansion beyond the U.S.—perhaps not at a double-digit pace, as you mentioned, yet still quite robust, with strong potential in that region. Thanks, Danny.

Falko Friedrichs

analyst
#80

Alright, thanks.

Danny Bar-Zohar

executive
#81

There's time for just one more question.

Operator

operator
#82

I appreciate that.

Danny Bar-Zohar

executive
#83

Thanks, Sarah. We’ve got room for one final question, please.

Operator

operator
#84

Thanks. Our final question this afternoon comes from Simon Baker at Rothschild & Co. Go right ahead.

Simon Baker

analyst
#85

Thanks for fitting me in. I’ll keep this short. First, coming back to what Sachin asked about Pergoveris. Danny, I understand you’d rather not get into possible US labels. Could you point out the main distinctions between the European marketing authorizations for Pergoveris and GONAL-f, and how has that shown up in European territories when it comes to share? Turning to Charles’ question about life sciences and CDMOs. Jean-Charles, what I took from your explanation of this strategic decision-making framework was that the outcomes were either we retain it or we divest it. Are there outcomes in which you would raise your exposure to the CDMO space if that were judged consistent with your wider strategic ambitions? Thanks very much.

Jean-Charles Wirth

executive
#86

I'll begin with the CDMO question. Whether we retain it, divest it, or put more money into it — right now, I'm not able to say. There isn't much more I can share. All the options are being evaluated, so stay tuned, there's more to come. I'd say I'll leave it at that for now.

Danny Bar-Zohar

executive
#87

Simon, on Pergoveris — I hope I understood your question correctly. I'm not certain I did. You were asking about how the labels for GONAL-f and Pergoveris differ in Europe.

Simon Baker

analyst
#88

Yeah. Regarding the, yeah, the characteristics — which points would you highlight as the main things that set the two products apart?

Danny Bar-Zohar

executive
#89

All right. So the two products — GONAL-f, as you know, is the sole recombinant FSH available on the market. Pergoveris, meanwhile, is a fixed-dose combination of recombinant FSH and LH. Because of that, it fits far better with IVF treatment for patients of advanced maternal age, who are also lacking LH. What typically happens is you begin with FSH, and then, when needed, you add extra injections containing the LH component. With this fixed-dose combination, you can address that patient population much more effectively, with excellent results. As I mentioned, the drug — I'm referring to Pergoveris — has grown over the last 5 years at a CAGR of 20% across Europe and Asia Pacific, for instance, the Middle East and Latin America. The potential is very high, and we believe it will be high in China as well once it gets in, and potentially in the U.S. in the second half.

Simon Baker

analyst
#90

Thanks a lot — that's great.

Operator

operator
#91

Thanks. At this point I'll pass things over to Belén for some closing comments. Thank you.

Belén Garijo

executive
#92

Thanks, Sarah. As you're aware, this marks my final quarterly and yearly call. So for that reason, I wanted my closing remarks to run a little longer. As I've mentioned before, I'm genuinely looking forward to meeting many of you in my new role. Reflecting today on the time I've spent at Merck, the first thing I should say is that working here has been enormously enjoyable for me. When I came on board in 2011, the company had only just started a period of transformation unlike anything before. Along with big acquisitions such as MilliporeSigma Aldrich and Versum, I took on the job of reshaping our healthcare business for a new era of patient care. In 2017, we brought out BAVENCIO, MAVENCLAD, and TEPMETKO — three products that returned healthcare to growth. We moved past our European origins to establish a genuinely global footprint across growth markets, especially China, where we built a business from the ground up that reached above EUR 1 billion in sales and meaningfully strengthened our healthcare position. That decade shaped the globally diversified company I took over as CEO of in 2021. Across the last 5 years, my aim was for Merck to become not just bigger but better as well. Since 2020, we've grown sales by 20%.

Belén Garijo

executive
#93

Our earnings growth actually outpaced that, and we brought net debt down by 20%, while headcount and assets went up only modestly. This happened during one of the most turbulent stretches in modern times: the pandemic, the war in Europe, and mounting geopolitical tension. Every single challenge has tested us, and every single challenge has left us stronger. Beyond delivering strong financial results, we expanded selectively through high-quality M&As, including Mirus Bio, UnitySC, and SpringWorks. That string of pearls approach sharpens where we focus on key growth fields, such as bioprocessing, semiconductors, and rare diseases. We also streamlined the portfolio by divesting businesses, among them Consumer Health, Biosimilars, Surface Solutions. At the same time, we shored up our resilience very early on, especially in Life Science and Electronics, by putting several billion EUR into our global footprint through our region for regional strategy. In my view, Merck is exceptionally well-positioned for the next chapter, ready to lead in the breakthrough markets that will define the coming decade, from novel modalities to the materials powering chips for AI. As of today, the preparations for handing the reins of leadership to Kai Beckmann are very advanced, as he already mentioned. I know Kai and the team have everything they need to keep reaching higher.

Belén Garijo

executive
#94

I'd like to take this moment to express sincere gratitude to our teams across the globe, as well as to our investors and to every analyst who follows us. Thank you for the confidence you've placed in us, and I look forward to seeing many of you in my new mandate, my new job. Many thanks, and farewell.

Operator

operator
#95

Thank you. Ladies and gentlemen, we appreciate you joining us. That brings this call to a close. You're free to disconnect now.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Merck KGaA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Merck KGaA earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Merck KGaA or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.